Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.

@article{Klasa2002RandomizedPI,
  title={Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.},
  author={Richard J Klasa and R. Michael Meyer and Chaim Shustik and Carol Anne Sawka and Anne C. Smith and Raymond Gu{\'e}vin and Andrew W. Maksymiuk and Morel Rubinger and Martin Samosh and Suzanne Laplante and J Grenier},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2002},
  volume={20 24},
  pages={4649-54}
}
PURPOSE To compare in a phase III study the safety and efficacy of fludarabine to that of cyclophosphamide, vincristine, and prednisone (CVP) in recurrent, low-grade, non-Hodgkin's lymphoma after previous response to systemic treatment. PATIENTS AND METHODS Patients were randomized to fludarabine (25 mg/m(2) intravenously on days 1 to 5, every 28 days) or CVP (cyclophosphamide 750 mg/m(2) and vincristine 1.2 mg/m(2) both intravenously on day 1 and prednisone 40 mg/m(2) orally on days 1 to 5… CONTINUE READING
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…